ArticleDevelopment (Cambridge, England)2017
MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Development (Cambridge, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05286788 (Phase 2 Study of the MEK Inhibitor MEKTOVI®), which is not on this map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Who cites it
53 citing papers in PubMed, 79 citations in OpenAlex.
- The role of stem cells in pituitary tumour formation.Endocrine-related cancer · 2026Review
- Comparative transcriptomic analysis of embryonic stem cells across mammalian species.iScience · 2026Article
- Unraveling the pleiotropic effects of CCR2-dependent signal transduction in fibrosis development.Theranostics · 2026Review
- Deficiency of anterior pituitary hormones in Noonan syndrome and its impact on response to growth hormone therapy.World journal of clinical pediatrics · 2025Article
- Targeted therapy of papillary craniopharyngioma.Medical oncology (Northwood, London, England) · 2025Review
- Characterizing resistant cellular states in nasopharyngeal carcinoma during EBV lytic induction.Oncogene · 2025Article
- AKT1 as a therapeutic target for platinum-resistant SOX2 positive ovarian cancer cells.Scientific reports · 2025Article
- Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches.Frontiers in endocrinology · 2025Review
- Integrated transcriptomics of human blood vessels defines a spatially controlled niche for early mesenchymal progenitor cells.Developmental cell · 2024Article
- Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.Acta neuropathologica communications · 2024Article
- Topographical distribution and prevalence of basal duct-like recess sign in a cohort of Papillary Craniopharyngioma-novel findings and implications.Neuroradiology · 2024Article
- Pituitary stem cells: past, present and future perspectives.Nature reviews. Endocrinology · 2024Review
- Bta-miR-181d and Bta-miR-196a mediated proliferation, differentiation, and apoptosis in Bovine Myogenic Cells.Journal of animal science · 2024Article
- Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024Review
- Review
- Clinical Significance of Plasma Leptin and Its Receptors mRNA Expression in Craniopharyngiomas: A Prospective Study.Biomolecules · 2023Article
- Pituitary Tumorigenesis-Implications for Management.Medicina (Kaunas, Lithuania) · 2023Review
- The molecular pathogenesis of craniopharyngiomas.Archives of endocrinology and metabolism · 2023Review
- BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience.Frontiers in oncology · 2023Review
- Pathological Diagnosis of Adult Craniopharyngioma on MR Images: An Automated End-to-End Approach Based on Deep Neural Networks Requiring No Manual Segmentation.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Scott HastonDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK scott.haston.13@ucl.ac.uk j.martinez-barbera@ucl.ac.uk.ORCID 0000-0003-3928-4808
Sara PozziDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Gabriela CarrenoDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Saba ManshaeiDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Leonidas PanousopoulosDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Jose Mario Gonzalez-MeljemDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
John R AppsDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Alex VirasamiDepartment of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3NN, UK.
Selvam ThavarajHead and Neck Pathology, Dental Institute, King's College London, London SE1 9RT, UK.
Alice GutteridgeDepartment of Pathology, UCL Cancer Institute, London WC1E 6DD, UK.
Tim ForshewDepartment of Pathology, UCL Cancer Institute, London WC1E 6DD, UK.
Richard MaraisMolecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
Sebastian BrandnerDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.
Thomas S JacquesDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Cynthia L AndoniadouCentre for Craniofacial and Regenerative Biology, King's College London, London SE1 9RT, UK.
Juan Pedro Martinez-BarberaDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK scott.haston.13@ucl.ac.uk j.martinez-barbera@ucl.ac.uk.ORCID 0000-0002-5292-7276
University College London · GBCRUK Lung Cancer Centre of Excellence · GBGreat Ormond Street Hospital for Children NHS Foundation Trust · GBKing's College London · GBNational Hospital for Neurology and Neurosurgery · GBUniversity of Manchester · GB
Funding
Cancer Research UK 22902Cancer Research UK 23615Medical Research Council G0700089Medical Research Council G0701018Medical Research Council G1100578Medical Research Council MC_PC_15004Medical Research Council MR/L016729/1Medical Research Council MR/M000125/1Medical Research Council MR/N004272/1Wellcome Trust
Abstract
Despite the importance of the RAS-RAF-MAPK pathway in normal physiology and disease of numerous organs, its role during pituitary development and tumourigenesis remains largely unknown. Here, we show that the over-activation of the MAPK pathway, through conditional expression of the gain-of-function alleles
Indexed as
AnimalsCell DifferentiationCell ProliferationCraniopharyngiomaEmbryonic Stem CellsFemaleGene Expression Regulation, DevelopmentalHomeodomain ProteinsHumansMAP Kinase Signaling SystemMiceMice, Mutant StrainsMice, TransgenicMutant ProteinsPituitary GlandPituitary NeoplasmsBraf protein, mouseHesx1 protein, mouseHomeodomain ProteinsHras protein, mouseMutant ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Repressor ProteinsSOX2 protein, humanSox2 protein, mouseSOXB1 Transcription FactorsMousePapillary craniopharyngiomaPituitary developmentSox2Tumour
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05286788ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.